Comparative analysis of mortality and hospital expenditure in patients with gastroenterological cancer: Thailand and United States.

Authors

null

Thanathip Suenghataiphorn

King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Thanathip Suenghataiphorn , Wasin Laohavinij , Tuntanut Lohawatcharagul

Organizations

King Chulalongkorn Memorial Hospital, Bangkok, Thailand, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Research Funding

No funding sources reported

Background: Concerns about rising health care cost and quality of care has been a major health issue worldwide. Gastrointestinal (GI) cancer accounts for one-quarter of the global cancer incidence. However, there are limited evidence, which demonstrates the differences in clinical outcome and economic burden of GI cancer when comparing between health care setting of developed and developing countries. Methods: Two data sources were analyzed: (i) The 2020 U.S. National Inpatient Sample (NIS) involving patients that were primarily discharged with gastroenterological cancer, and (ii) data at tertiary care center in Thailand used for this comparative study, with similar period and conditions. Participants were identified using relevant ICD-10 CM codes. Adjusted odds ratios (aORs) for specified outcomes were calculated through multivariate logistic and linear regression analyses. Participants are divided into those who experienced mortality and those who survived. We report crude mortality rates and expenditure outcomes. Statistical significance was established at a p-value of 0.05. Results: We identified 9,299 Thai records and estimated 216,859 US records with a primary diagnosis of GI cancer at discharge. Of these, 2.15% (200/9,299) of the Thai records and 3.82% (8,285/216,859) of the US records died. In a multivariate analysis, death during hospitalization is associated with higher length of stay (Thai: b = 18.10, 95% CI (16.71, 19.49), p < 0.001), (US: b = 3.38, 95% CI 3.38 (2.14, 4.63), p < 0.001) and higher hospitalization charges (Thai: b = 155,530.02 THB, 95% CI (141,805.10, 169,254.80), p < 0.001), (US: b = 46,882.44 USD, 95% CI (31,629.51, 62,135.37), p <0.001). Subpopulation analysis revealed similar significant results. We observed higher increased length of stay in Thailand, whereas higher crude mortality rate and hospitalization charges was observed in the United States. Conclusions: In both Thailand and United States, mortality in patient with GI cancer is associated with increase in length of stay and higher hospitalization expenses. However, the magnitude of difference in each outcome differs between two countries. Future studies investigating health care costs, cultural role and clinical outcomes may provide insights for cost-reduction strategies, while maintaining or improving the current standard of care in this population group.

Number of hospitalizations, with total estimations and crude mortality rates.

Thailand (Tertiary Center)United States
Type Of CancerDiedTotalDiedTotal
Upper GI tract Cancer42 (3.75%)1,1191,845 (5.19%)35,539
Colon Cancer27 (0.90%)2,9842,035 (2.54%)80,114
Rectum Cancer19 (0.89%)2,145644 (1.76%)36,463
Pancreas and Biliary Cancer38 (3.69%)1,0312,001 (4.64%)43,094
Liver Cancer74 (3.67%)2,0191,705 (8.06%)21,141
Gastroenterological Cancer200 (2.15%)9,2998,285 (3.82%)216,859

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session A

Track

Gastrointestinal Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Quality of Care,Healthcare Equity and Access to Care,Population Health,Viral-Mediated Malignancies

Sub Track

Real-World Evidence/Real-World Data

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 79)

DOI

10.1200/JCO.2024.42.23_suppl.79

Abstract #

79

Poster Bd #

F1

Abstract Disclosures

Similar Abstracts

Abstract

2021 Genitourinary Cancers Symposium

Hospital competition, quality, and cost of prostate cancer care.

First Author: Ravishankar Jayadevappa

First Author: Vaishali Deenadayalan